NCT04692181: SYN-004 Safety and Tolerability in Allo-HCT Subjects |
|
|
| Recruiting | 1b/2a | 36 | US | SYN-004, Ribaxamase or Placebo | Theriva Biologics, Inc., Washington University School of Medicine | 121121000119106, Acute Graft-versus-host Reaction Following Bone Marrow Transplant (Disorder) | 12/24 | 12/25 | | |
NCT04363242: A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions |
|
|
| Active, not recruiting | 1 | 22 | US | SYN125, SYN004 | Synermore Biologics Co., Ltd., Synermore Biologics USA Limited | Epithelial Carcinoma, Solid Tumor | 07/23 | 09/23 | | |